Filing Details

Accession Number:
0001209191-21-021769
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-18 16:35:34
Reporting Period:
2021-03-16
Accepted Time:
2021-03-18 16:35:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1094038 Marker Therapeutics Inc. MRKR Pharmaceutical Preparations (2834) 880277072
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1250195 Steve Elms C/O Marker Therapeutics, Inc.
3200 Southwest Freeway, Suite 2500
Houston TX 77027
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-16 1,142,857 $1.75 3,142,857 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 17,022 Direct
Footnotes
  1. The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.